HOHidetaka S. Oshima

Hidetaka S. Oshima

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hidetaka S. Oshima has a total of 54 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Structural insights into the ligand and G protein recognition by P2Y13R

    by Hidetaka S. Oshima, Hiroaki Akasaka, Fumiya K. Sano, Osamu Nureki

  • Open Access

    Cryo-EM structure of the bicarbonate receptor GPR30

    by Shota Kaneda, Airi Jo-Watanabe, Hiroaki Akasaka, Hidetaka S Oshima, Takehiko Yokomizo, Wataru Shihoya, Osamu Nureki

    G-protein-coupled receptor 30 (GPR30) is a bicarbonate receptor that plays a vital role in cellular responses to extracellular pH and ion homeostasis. Despite its significance, the mechanisms by which GPR30 interacts with bicarbonate ions remain elusive. There is no consensus on a drug that targets GPR30, and difficulties in pharmacological analyses have limited biological and drug discovery research on GPR30. Here, we present the cryo-electron microscopy structure of human GPR30 in the presence of bicarbonate ions, at 3.15 Ã… resolution. Our structure reveals unique extracellular pockets and critical residues for bicarbonate binding and activation. Functional assays demonstrate that mutations in these residues impair bicarbonate-induced GPR30 activation, underscoring their importance in receptor function. This study also provides insights into G-protein coupling, highlighting the structural divergence between GPR30 and other GPCRs. Our findings not only advance the understanding of the role of GPR30 in pH homeostasis but also pave the way for the development of high-affinity drugs targeting GPR30 for therapeutic interventions in diseases associated with acid-base imbalance.


  • Open Access

    Molecular mechanism of naturally-encoded signaling-bias at the complement anaphylatoxin receptors

    by Divyanshu Tiwari, Kazuhiro Sawada, Annu Dalal, Sudha Mishra, Xaria X. Li, Joshua C. Dent, Kiae Kim, Manish K. Yadav, Nabarun Roy, Manisankar Ganguly, et al.

    The conceptual framework of biased signaling has revolutionized our understanding of GPCR signaling and regulatory paradigms, and greatly impacted the efforts focused on the discovery of GPCR-targeted therapeutics. However, the mechanistic basis of biased signaling remains primarily defined based on synthetic ligands and receptor mutants with relatively limited progress in understanding naturally-encoded signaling-bias. Here, we present fundamental molecular and structural insights into naturally-encoded signaling-bias at the complement anaphylatoxin C5a receptors namely, C5aR1 and C5aR2. We first discover that C5a -d-Arg , the naturally-occurring version of C5a lacking the terminal arginine, exhibits robust G-protein signaling-bias at C5aR1, characterised by attenuated βarr recruitment. This signaling-bias manifests in both cytokine release from primary human immune cells, and in vivo, during neutrophil mobilization. We combine the cryo-EM structures of C5a/C5a -d-Arg -C5aR1 complexes with MD simulation, site-directed mutagenesis, and cellular experiments to elucidate that the G-protein-bias exhibited by C5a -d-Arg results from a distinct orientation of TM7 and helix 8 in C5aR1 leading to inefficient GRK recruitment and receptor phosphorylation. Next, we determine the first cryo-EM structures of C5aR2, a naturally-encoded β-arrestin-biased receptor, in an apo state, complexed with the natural agonists C5a and C5a -d-Arg , and three peptide agonists including a first-in-class, newly discovered C5aR2-selective agonist, R8Y. These structural snapshots reveal key differences between the binding of C5a and C5a - d-Arg to C5aR1 and C5aR2, and provide a molecular basis of functional specialization at these two receptors. Moreover, the structural insights also allow us to decipher the molecular basis of naturally-encoded signaling-bias at C5aR2 originating from a shallower cytoplasmic interface with hydrophobic interior pocket that is not permissive to efficient G-protein-coupling and activation. Finally, we also engineer and characterize loss-of-function and gain-of-function variants of C5aR1 and C5aR2, which in turn corroborate and validate the structural observations presented here. Collectively, our findings offer crucial insights into previously lacking molecular mechanisms of the naturally-encoded signaling-bias at GPCRs, which have broad implications not only for the general framework of biased-signaling, but also for novel therapeutic design.


  • Open Access

    Structural insights into ligand recognition and G protein preferences across histamine receptors

    by Yuma Matsuzaki, Fumiya K. Sano, Hidetaka S. Oshima, Hiroaki Akasaka, Kazuhiro Kobayashi, Tatsuki Tanaka, Yuzuru Itoh, Wataru Shihoya, Yoshiaki Kise, Tsukasa Kusakizako, et al.

    Histamine exerts critical physiological roles by activating four receptor subtypes, each exhibiting a specific G protein preference. Among these, the histamine H4 receptor (H4R) modulates chemotaxis and interferon production through Gi protein activation, suggesting its therapeutic potential. Despite its physiological significance, the mechanisms underlying H4R signalling and G protein preference across histamine receptors remain poorly understood. Here, we present the cryo-electron microscopy structure of the H4R-Gi complex, revealing unique mechanisms of histamine recognition and receptor activation. We further solved the structures of the histamine H1 receptor (H1R) bound to the non-canonical G proteins Gi and Gs. Through a combination of functional and computational analyses, we identified the intracellular loop 2 as a critical determinant of G protein preference in H1R and H4R. Collectively, our comprehensive study revealed the structural basis for distinct mechanisms of ligand recognition and receptor activation, offering a profound insight into G protein preference across receptor subtypes.


  • Open Access

    Structural insights into the agonist selectivity of the adenosine A3 receptor

    by Hidetaka S. Oshima, Akiko Ogawa, Fumiya K. Sano, Hiroaki Akasaka, Tomoyoshi Kawakami, Aika Iwama, Hiroyuki H. Okamoto, Chisae Nagiri, Fan-Yan Wei, Wataru Shihoya, et al.

    Adenosine receptors play pivotal roles in physiological processes. Adenosine A3 receptor (A3R), the most recently identified adenosine receptor, is expressed in various tissues, exhibiting important roles in neuron, heart, and immune cells, and is often overexpressed in tumors, highlighting the therapeutic potential of A3R-selective agents. Recently, we identified RNA-derived N6-methyladenosine (m6A) as an endogenous agonist for A3R, suggesting the relationship between RNA-derived modified adenosine and A3R. Despite extensive studies on the other adenosine receptors, the selectivity mechanism of A3R, especially for A3R-selective agonists such as m6A and namodenoson, remained elusive. Here, we identify tRNA-derived N6-isopentenyl adenosine (i6A) as an A3R-selective ligand via screening of modified nucleosides against the adenosine receptors. Like m6A, i6A is found in the human body and may be an endogenous A3R ligand. Our cryo-EM analyses elucidate the A3R-Gi complexes bound to adenosine, 5’-N-ethylcarboxamidoadenosine (NECA), m6A, i6A, and namodenoson at overall resolutions of 3.27 Å (adenosine), 2.86 Å (NECA), 3.19 Å (m6A), 3.28 Å (i6A), and 3.20 Å (namodenoson), suggesting the selectivity and activation mechanism of A3R. We further conduct structure-guided engineering of m6A-insensitive A3R, which may aid future research targeting m6A and A3R, providing a molecular basis for future drug discovery.


  • Open Access

    Structure and dynamics of the pyroglutamylated RF-amide peptide QRFP receptor GPR103

    by Aika Iwama, Ryoji Kise, Hiroaki Akasaka, Fumiya K. Sano, Hidetaka S. Oshima, Asuka Inoue, Wataru Shihoya, Osamu Nureki

    Pyroglutamylated RF-amide peptide (QRFP) is a peptide hormone with a C-terminal RF-amide motif. QRFP selectively activates a class A G-protein-coupled receptor (GPCR) GPR103 to exert various physiological functions such as energy metabolism and appetite regulation. Here, we report the cryo-electron microscopy structure of the QRFP26-GPR103-Gq complex at 3.19 Ã… resolution. QRFP26 adopts an extended structure bearing no secondary structure, with its N-terminal and C-terminal sides recognized by extracellular and transmembrane domains of GPR103 respectively. This movement, reminiscent of class B1 GPCRs except for orientation and structure of the ligand, is critical for the high-affinity binding and receptor specificity of QRFP26. Mutagenesis experiments validate the functional importance of the binding mode of QRFP26 by GPR103. Structural comparisons with closely related receptors, including RY-amide peptide-recognizing GPCRs, revealed conserved and diversified peptide recognition mechanisms, providing profound insights into the biological significance of RF-amide peptides. Collectively, this study not only advances our understanding of GPCR-ligand interactions, but also paves the way for the development of novel therapeutics targeting metabolic and appetite disorders and emergency medical care.


  • Open Access

    Cryo-EM structure of the bicarbonate receptor GPR30

    by Shota Kaneda, Airi Jo-Watanabe, Hiroaki Akasaka, Hidetaka S. Oshima, Takehiko Yokomizo, Wataru Shihoya, Osamu Nureki

    G-protein-coupled receptor 30 (GPR30) is a bicarbonate receptor that plays a vital role in cellular responses to extracellular pH and ion homeostasis. Despite its significance, the mechanisms by which GPR30 interacts with bicarbonate ions remain elusive. There is no consensus on a drug that targets GPR30, and difficulties in pharmacological analyses have limited biological and drug discovery research on GPR30. Here, we present the cryo-electron microscopy structure of human GPR30 in the presence of bicarbonate ions, at 3.15 Ã… resolution. Our structure reveals unique extracellular pockets and critical residues for bicarbonate binding and activation. Functional assays demonstrate that mutations in these residues impair bicarbonate-induced GPR30 activation, underscoring their importance in receptor function. This study also provides insights into G-protein coupling, highlighting the structural divergence between GPR30 and other GPCRs. Our findings not only advance the understanding of the role of GPR30 in pH homeostasis but also pave the way for the development of high-affinity drugs targeting GPR30 for therapeutic interventions in diseases associated with acid-base imbalance.

  • Open Access

    Structural insights into the agonist selectivity and structure-based engineering of the adenosine A3 receptor

    by Hidetaka S. Oshima, Akiko Ogawa, Fumiya K. Sano, Hiroaki Akasaka, Tomoyoshi Kawakami, Hiroyuki H. Okaomto, Aika Iwama, Chisae Nagiri, Fan-Yan Wei, Wataru Shihoya, et al.

    Adenosine receptors, expressed across various tissues, play pivotal roles in physiological processes and are implicated in diverse diseases, including neurological disorders and inflammation, highlighting the therapeutic potential of receptor-selective agents. The Adenosine A3 receptor (A 3 R), the last identified adenosine receptor, is also activated by breakdown products of post-transcriptionally modified tRNA and exhibits dual roles in neuron, heart, and immune cells, and is often overexpressed in tumors, making it a target for anticancer therapy. Despite extensive studies on the other adenosine receptors, the structure and activation mechanism of A 3 R, especially by selective agonists like N 6 -methyladenosine (m 6 A) and namodenoson, remained elusive. Here, we identified N 6 -isopentenyl adenosine (i 6 A), a novel A 3 R-selective ligand, via comprehensive modified adenosine library screening. Cryo-EM analyses of A 3 R-G i signaling complexes with two nonselective and three selective agonists revealed the structural basis for A 3 R activation. We further conducted structure-guided engineering of m 6 A-insensitive A 3 R, which would greatly facilitate future discoveries of the physiological functions of the selective activation of A 3 R by modified adenosines. Our results clarify the selective activation of adenosine receptors, providing the basis for future drug discovery.


  • Open Access

    Optimizing cryo-EM structural analysis of Gi-coupling receptors via engineered Gt and Nb35 application

    by Hidetaka S. Oshima, Fumiya K. Sano, Hiroaki Akasaka, Aika Iwama, Wataru Shihoya, Osamu Nureki


  • Open Access

    Structure and dynamics of the RF-amide QRFP receptor GPR103

    by Aika Iwama, Hiroaki Akasaka, Fumiya K. Sano, Hidetaka S. Oshima, Wataru Shihoya, Osamu Nureki

    Pyroglutamylated RF amide peptide (QRFP) is a type of peptide hormone with a C-terminal RF-amide motif. QRFP selectively activates class-A categorized GPCR, GPR103 to exert various physiological functions such as energy metabolism and appetite regulation. Here, we report the cryo-electron microscopy structure of the QRFP-GPR103-G q complex at 3.3 Ã… resolution. Unlike class-A GPCR, QRFP adopts an extended structure baring no secondary structure, with its N-terminal and C-terminal sides recognized by extracellular and transmembrane domains, respectively, of GPR103. The C-terminal heptapeptide of QRFP penetrates into the orthosteric pocket to act in receptor activation. Particularly, the residues that recognize the RF-amide are highly conserved in the RF-amide receptors. Notably, the unique N-terminal helix-loop-helix of the receptor traps the N-terminal side of QRFP with the pendulum-like motion to guide QRFP into the ligand-binding pocket. This movement, reminiscent of class B1 GPCRs except for orientation and structure of the ligand, is critical for the high affinity binding and receptor specificity of QRFP. Structural comparisons with closely related receptors, including RY-amide peptide-recognizing GPCRs, revealed conserved and diversified peptide recognition mechanisms, providing profound insights into the biological significance of RF-amide peptides. This study not only advances our understanding of GPCR-ligand interactions, but also paves the way for the development of novel therapeutics targeting metabolic and appetite disorders and emergency medical care.